Rare Side Effect of Ozempic and Similar Drugs on the Rise
New research indicates that GLP-1 weight-loss drugs like Ozempic may interfere with PET-CT scans by causing unusual FDG uptake patterns, potentially leading to misdiagnoses, unnecessary tests, or delayed treatment. Experts recommend documenting medication use during scans and developing guidelines to address this emerging issue.